BHC (Bausch Health) NonCurrent Deferred Revenue: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BHC Bausch Health Companies Inc BHC
58 GF Score
Price $6.81
GF Value $7.44
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Bausch Health NonCurrent Deferred Revenue?

Bausch Health BHC -1.16% 58 NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.44 (Fairly Valued). The stock has 4 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Bausch Health's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0 Mil.

Bausch Health NonCurrent Deferred Revenue Related Terms

Bausch Health NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Bausch Health's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health NonCurrent Deferred Revenue Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bausch Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BHC
58GF Score
Bausch Health Companies Inc BHC
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0 Mil mean?
Bausch Health (BHC) has a NonCurrent Deferred Revenue of $0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Bausch Health and its competitors.
Is Bausch Health's NonCurrent Deferred Revenue too high?
Bausch Health's current NonCurrent Deferred Revenue is $0 Mil. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's NonCurrent Deferred Revenue compare to ZTS?
Bausch Health's NonCurrent Deferred Revenue of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Bausch Health and its competitors. Bausch Health's current NonCurrent Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Fairly Valued. The stock's GF Value™ is $7.44, compared to a current price of $6.81 — trading 8.5% below its estimated fair value. The current NonCurrent Deferred Revenue is $0 Mil. Bausch Health's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Bausch Health (BHC), the current NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of $6.81 is trading 8.5% below its estimated GF Value™ of $7.44. GuruFocus considers Bausch Health to be Fairly Valued.

Key valuation signals for BHC:

  • NonCurrent Deferred Revenue: $0 Mil
  • GF Value™: $7.44 vs. price of $6.81 (8.5% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score

Get the complete analysis for BHC

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.81
Price
$7.44
GF Value